| KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis Z Lohinai, T Klikovits, J Moldvay, G Ostoros, E Raso, J Timar, K Fabian, ... Scientific reports 7 (1), 39721, 2017 | 99 | 2017 |
| Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy M Cserepes, G Ostoros, Z Lohinai, E Raso, T Barbai, J Timar, A Rozsas, ... European journal of cancer 50 (10), 1819-1828, 2014 | 91 | 2014 |
| Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma Z Lohinai, MA Hoda, K Fabian, G Ostoros, E Raso, T Barbai, J Timar, ... Journal of thoracic oncology 10 (5), 738-746, 2015 | 90 | 2015 |
| Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients Y Ni, Z Lohinai, Y Heshiki, B Dome, J Moldvay, E Dulka, G Galffy, J Berta, ... The ISME journal 15 (11), 3207-3220, 2021 | 66 | 2021 |
| High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma MA Hoda, A Rozsas, E Lang, T Klikovits, Z Lohinai, S Torok, J Berta, ... Oncotarget 7 (12), 13388, 2016 | 61 | 2016 |
| Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution D Dora, C Rivard, H Yu, P Bunn, K Suda, S Ren, S Lueke Pickard, ... Molecular Oncology 14 (9), 1947-1965, 2020 | 60 | 2020 |
| New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study T Klikovits, Z Lohinai, K Fabian, M Gyulai, M Szilasi, J Varga, E Baranya, ... Lung Cancer 126, 139-148, 2018 | 37 | 2018 |
| Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study Z Megyesfalvi, N Barany, A Lantos, Z Valko, O Pipek, C Lang, ... The Journal of Pathology 257 (5), 674-686, 2022 | 35 | 2022 |
| Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma L Reiniger, V Téglási, O Pipek, L Rojkó, T Glasz, A Vágvölgyi, I Kovalszky, ... Acta oncologica 58 (8), 1087-1094, 2019 | 28 | 2019 |
| Neutrophil–lymphocyte ratio is prognostic in early stage resected small-cell lung cancer Z Lohinai, L Bonanno, A Aksarin, A Pavan, Z Megyesfalvi, B Santa, ... PeerJ 7, e7232, 2019 | 28 | 2019 |
| Characterization of tumor-associated macrophages and the immune microenvironment in limited-stage neuroendocrine-high and-low small cell lung cancer D Dora, C Rivard, H Yu, SL Pickard, V Laszlo, T Harko, Z Megyesfalvi, ... Biology 10 (6), 502, 2021 | 27 | 2021 |
| KRAS mutations predict response and outcome in advanced lung adenocarcinoma patients receiving first-line bevacizumab and platinum-based chemotherapy ÁK Ghimessy, Á Gellert, E Schlegl, B Hegedus, E Raso, T Barbai, J Timar, ... Cancers 11 (10), 1514, 2019 | 25 | 2019 |
| Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases Z Lohinai, Z Megyesfalvi, K Suda, T Harko, S Ren, J Moldvay, V Laszlo, ... Translational lung cancer research 8 (6), 938, 2019 | 17 | 2019 |
| From bench to bedside: attempt to evaluate repositioning of drugs in the treatment of metastatic small cell lung cancer (SCLC) Z Lohinai, P Dome, Z Szilagyi, G Ostoros, J Moldvay, B Hegedus, B Dome, ... PloS one 11 (1), e0144797, 2016 | 15 | 2016 |
| Implication of the gut microbiome and microbial-derived metabolites in immune-related adverse events: emergence of novel biomarkers for cancer immunotherapy D Dora, SMZ Bokhari, K Aloss, P Takacs, JZ Desnoix, G Szklenárik, ... International journal of molecular sciences 24 (3), 2769, 2023 | 10 | 2023 |
| Loss of STING expression is prognostic in non–small cell lung cancer Z Lohinai, D Dora, C Caldwell, CJ Rivard, K Suda, H Yu, G Rivalland, ... Journal of Surgical Oncology 125 (6), 1042-1052, 2022 | 10 | 2022 |
| P3. 12-13 expression of the immune checkpoint axis-PVR/TIGIT in small cell lung cancer H Yu, C Koczara, Z Lohinai, A Badzio, P Czapiewski, B Döme, J Moldvay, ... Journal of Thoracic Oncology 13 (10), S974-S975, 2018 | 10 | 2018 |
| Protein expression of immune checkpoints STING and MHCII in small cell lung cancer D Dora, C Rivard, H Yu, SL Pickard, V Laszlo, T Harko, Z Megyesfalvi, ... Cancer Immunology, Immunotherapy 72 (3), 561-578, 2023 | 9 | 2023 |
| Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions B Seelbinder, Z Lohinai, R Vazquez-Uribe, S Brunke, X Chen, ... Nature Communications 14 (1), 2673, 2023 | 8 | 2023 |
| CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer Q Liu, M Qiao, Z Lohinai, S Mao, Y Pan, Y Wang, S Yang, F Zhou, T Jiang, ... Lung Cancer 162, 194-202, 2021 | 8 | 2021 |
